381 related articles for article (PubMed ID: 30285841)
41. Clinical phenotypes of IgG4-related disease reflect different prognostic outcomes.
Lanzillotta M; Campochiaro C; Mancuso G; Ramirez GA; Capurso G; Falconi M; Dagna L; Della-Torre E
Rheumatology (Oxford); 2020 Sep; 59(9):2435-2442. PubMed ID: 32591828
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and safety of rituximab for IgG4-related pancreato-biliary disease: A systematic review and meta-analysis.
Lanzillotta M; Della-Torre E; Wallace ZS; Stone JH; Karadag O; Fernández-Codina A; Arcidiacono PG; Falconi M; Dagna L; Capurso G
Pancreatology; 2021 Oct; 21(7):1395-1401. PubMed ID: 34244040
[TBL] [Abstract][Full Text] [Related]
43. Quantitative measurement of 18F-FDG PET/CT uptake reflects the expansion of circulating plasmablasts in IgG4-related disease.
Berti A; Della-Torre E; Gallivanone F; Canevari C; Milani R; Lanzillotta M; Campochiaro C; Ramirez GA; Bozzalla Cassione E; Bozzolo E; Pedica F; Castiglioni I; Arcidiacono PG; Balzano G; Falconi M; Gianolli L; Dagna L
Rheumatology (Oxford); 2017 Dec; 56(12):2084-2092. PubMed ID: 28977663
[TBL] [Abstract][Full Text] [Related]
44. Clinical characteristics and outcome of IgG4-related disease with hypocomplementemia: a prospective cohort study.
Peng L; Lu H; Zhou J; Zhang P; Li J; Liu Z; Wu D; Zhang S; Yang Y; Bai W; Wang L; Fei Y; Zhang W; Zhao Y; Zeng X; Zhang F
Arthritis Res Ther; 2021 Apr; 23(1):102. PubMed ID: 33827676
[TBL] [Abstract][Full Text] [Related]
45. Additive effect of leflunomide and glucocorticoids compared with glucocorticoids monotherapy in preventing relapse of IgG4-related disease: A randomized clinical trial.
Wang Y; Zhao Z; Gao D; Wang H; Liao S; Dong C; Luo G; Ji X; Li Y; Wang X; Zhao Y; Li K; Zhang J; Jin J; Zhang Y; Zhu J; Zhang J; Huang F
Semin Arthritis Rheum; 2020 Dec; 50(6):1513-1520. PubMed ID: 32113839
[TBL] [Abstract][Full Text] [Related]
46. Efficacy between high and medium doses of glucocorticoid therapy in remission induction of IgG4-related diseases: a preliminary randomized controlled trial.
Wu Q; Chang J; Chen H; Chen Y; Yang H; Fei Y; Zhang P; Zeng X; Zhang F; Zhang W
Int J Rheum Dis; 2017 May; 20(5):639-646. PubMed ID: 28556584
[TBL] [Abstract][Full Text] [Related]
47. New insights into immune cells cross-talk during IgG4-related disease.
Touzani F; Pozdzik A
Clin Immunol; 2019 Jan; 198():1-10. PubMed ID: 30419354
[TBL] [Abstract][Full Text] [Related]
48. Prognostic factors in IgG4-related disease: a long-term monocentric Chinese cohort study.
Zongfei J; Lingying M; Lijuan Z; Ying S; Rongyi C; Dongmei L; Xiufang K; Xiaomin D; Lili M; Huiyong C; Lindi J
Clin Rheumatol; 2021 Jun; 40(6):2293-2300. PubMed ID: 33151477
[TBL] [Abstract][Full Text] [Related]
49. IgG4-related disease in a multi-ethnic community: clinical characteristics and association with malignancy.
Poo SX; Tham CSW; Smith C; Lee J; Cairns T; Galliford J; Hamdulay S; Jacyna M; Levy JB; McAdoo SP; Roufosse C; Wernig F; Mason JC; Pusey CD; Tam FWK; Tomlinson JAP
QJM; 2019 Oct; 112(10):763-769. PubMed ID: 31225617
[TBL] [Abstract][Full Text] [Related]
50. IgG4-related uveitis. A French cohort and literature review.
Stuchfield-Denby E; De Sainte Marie B; Hie M; Hatchuel Y; Gerber A; Bencheikh S; Pugnet G; Groh M; Farhat MM; Urbina D; Ebbo M; Schleinitz N
Semin Arthritis Rheum; 2024 Feb; 64():152278. PubMed ID: 38000318
[TBL] [Abstract][Full Text] [Related]
51. Risk factors of relapse following glucocorticoid tapering in IgG4-related disease.
Sasaki T; Akiyama M; Kaneko Y; Yasuoka H; Suzuki K; Yamaoka K; Takeuchi T
Clin Exp Rheumatol; 2018; 36 Suppl 112(3):186-189. PubMed ID: 29846165
[TBL] [Abstract][Full Text] [Related]
52. Immunoglobulin G4-Related Disease Responder Index Correlates With the Risk of 1-Year Relapse in Type 1 Autoimmune Pancreatitis.
Rogger TM; De Marchi G; Brozzi L; Amodio A; Orsolini G; de Pretis N; Conti Bellocchi MC; Crinò SF; Gabbrielli A; Ciccocioppo R; Frulloni L
Pancreas; 2021 Jul; 50(6):879-881. PubMed ID: 34347736
[TBL] [Abstract][Full Text] [Related]
53. Glucocorticoids and steroid sparing medications monotherapies or in combination for IgG4-RD: a systematic review and network meta-analysis.
Omar D; Chen Y; Cong Y; Dong L
Rheumatology (Oxford); 2020 Apr; 59(4):718-726. PubMed ID: 31511884
[TBL] [Abstract][Full Text] [Related]
54. Recent progress on the treatment of type 1 autoimmune pancreatitis and IgG4-related disease.
Okazaki K; Ikeura T; Uchida K
Mod Rheumatol; 2023 Mar; 33(2):237-241. PubMed ID: 35737955
[TBL] [Abstract][Full Text] [Related]
55. Expansion and surface makers of age-associated B cells in IgG4-related disease.
Zhang P; Lu H; Peng Y; Sun R; Nie Y; Li J; Peng L; Zhang W
Clin Exp Rheumatol; 2024 Jan; 42(1):56-68. PubMed ID: 37470223
[TBL] [Abstract][Full Text] [Related]
56. Perspectives on current and emerging therapies for immunoglobulin G4-related disease.
Tanaka Y; Stone JH
Mod Rheumatol; 2023 Mar; 33(2):229-236. PubMed ID: 36408992
[TBL] [Abstract][Full Text] [Related]
57. Efficacy of Cyclophosphamide treatment for immunoglobulin G4-related disease with addition of glucocorticoids.
Yunyun F; Yu C; Panpan Z; Hua C; Di W; Lidan Z; Linyi P; Li W; Qingjun W; Xuan Z; Yan Z; Xiaofeng Z; Fengchun Z; Wen Z
Sci Rep; 2017 Jul; 7(1):6195. PubMed ID: 28733656
[TBL] [Abstract][Full Text] [Related]
58. Expansion of blood IgG
Heeringa JJ; Karim AF; van Laar JAM; Verdijk RM; Paridaens D; van Hagen PM; van Zelm MC
J Allergy Clin Immunol; 2018 May; 141(5):1831-1843.e10. PubMed ID: 28830675
[TBL] [Abstract][Full Text] [Related]
59. Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations.
Wallace ZS; Mattoo H; Carruthers M; Mahajan VS; Della Torre E; Lee H; Kulikova M; Deshpande V; Pillai S; Stone JH
Ann Rheum Dis; 2015 Jan; 74(1):190-5. PubMed ID: 24817416
[TBL] [Abstract][Full Text] [Related]
60. Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre study.
Shirakashi M; Yoshifuji H; Kodama Y; Chiba T; Yamamoto M; Takahashi H; Uchida K; Okazaki K; Ito T; Kawa S; Yamada K; Kawano M; Hirata S; Tanaka Y; Moriyama M; Nakamura S; Kamisawa T; Matsui S; Tsuboi H; Sumida T; Shibata M; Goto H; Sato Y; Yoshino T; Mimori T
Sci Rep; 2018 Jul; 8(1):10262. PubMed ID: 29980706
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
